CN110662743A - 作为fxr受体激动剂的内酰胺类化合物 - Google Patents

作为fxr受体激动剂的内酰胺类化合物 Download PDF

Info

Publication number
CN110662743A
CN110662743A CN201880034598.2A CN201880034598A CN110662743A CN 110662743 A CN110662743 A CN 110662743A CN 201880034598 A CN201880034598 A CN 201880034598A CN 110662743 A CN110662743 A CN 110662743A
Authority
CN
China
Prior art keywords
compound
group
optionally substituted
pharmaceutically acceptable
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880034598.2A
Other languages
English (en)
Other versions
CN110662743B (zh
Inventor
贺海鹰
余军
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd filed Critical NANJING MINGDE NEW DRUG RESEARCH AND DEVELOPMENT Co Ltd
Publication of CN110662743A publication Critical patent/CN110662743A/zh
Application granted granted Critical
Publication of CN110662743B publication Critical patent/CN110662743B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了式(Ⅰ)所示化合物、其光学异构体或其药学上可接受的盐，并涉及其在制备治疗FXR相关疾病药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201880034598.2A 2017-05-26 2018-05-25 作为fxr受体激动剂的内酰胺类化合物 Active CN110662743B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN201710384773 2017-05-26
CN2017103847738 2017-05-26
CN201710523080 2017-06-26
CN2017105230802 2017-06-26
CN2017108678632 2017-09-22
CN201710867863 2017-09-22
PCT/CN2018/088393 WO2018214959A1 (zh) 2017-05-26 2018-05-25 作为fxr受体激动剂的内酰胺类化合物

Publications (2)

Publication Number Publication Date
CN110662743A true CN110662743A (zh) 2020-01-07
CN110662743B CN110662743B (zh) 2022-09-30

Family

ID=64396264

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034598.2A Active CN110662743B (zh) 2017-05-26 2018-05-25 作为fxr受体激动剂的内酰胺类化合物

Country Status (8)

Country Link
US (1) US11339147B2 (zh)
EP (1) EP3632910B1 (zh)
JP (1) JP7266538B2 (zh)
KR (1) KR20200010483A (zh)
CN (1) CN110662743B (zh)
AU (1) AU2018272359B2 (zh)
CA (1) CA3064794A1 (zh)
WO (1) WO2018214959A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE054960T2 (hu) 2015-03-31 2021-10-28 Enanta Pharm Inc Epesav származékok, mint az FXR/TGR5 agonista és annak felhasználási módszerei
CN109906223A (zh) 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
KR20210097158A (ko) * 2018-11-26 2021-08-06 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 Fxr 작용제의 고체 형태, 결정 형태, 및 결정 형태 a, 및 이의 제조방법 및 이의 적용
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
EP3999101A1 (en) 2019-07-18 2022-05-25 ENYO Pharma Method for decreasing adverse-effects of interferon
CA3142904A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
CA3153062A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
JP2022550312A (ja) 2019-09-30 2022-12-01 ノバルティス アーゲー Ｆｘｒアゴニストの使用を含む処置
EP4076454A1 (en) 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
KR20220128402A (ko) 2020-01-15 2022-09-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) D형 간염 바이러스에 의한 감염을 치료하기 위한 fxr 작용제의 용도
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379774A (zh) * 1999-08-18 2002-11-13 阿斯特拉曾尼卡有限公司 化合物
WO2004063190A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
EP1690538A1 (en) * 2003-12-02 2006-08-16 Shionogi & Co., Ltd. Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
CN101877966A (zh) * 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021576A (en) 1989-10-27 1991-06-04 American Home Products Corporation 2-Anilino phenylacetic acid derivatives
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
KR100960793B1 (ko) 2009-06-29 2010-06-03 한국전력공사 저급 석탄의 고품위화 방법 및 장치
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1379774A (zh) * 1999-08-18 2002-11-13 阿斯特拉曾尼卡有限公司 化合物
WO2004063190A1 (en) * 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivates as ppar modulators
EP1690538A1 (en) * 2003-12-02 2006-08-16 Shionogi & Co., Ltd. Isoxazole derivative having agonistic activity against peroxisome proliferator-activated receptor
CN101877966A (zh) * 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂

Also Published As

Publication number Publication date
US20200190074A1 (en) 2020-06-18
WO2018214959A1 (zh) 2018-11-29
AU2018272359A1 (en) 2019-12-19
CA3064794A1 (en) 2018-11-29
US11339147B2 (en) 2022-05-24
JP7266538B2 (ja) 2023-04-28
JP2020521770A (ja) 2020-07-27
KR20200010483A (ko) 2020-01-30
RU2019139415A3 (zh) 2021-09-03
EP3632910B1 (en) 2024-07-17
RU2019139415A (ru) 2021-06-28
AU2018272359B2 (en) 2022-03-03
CN110662743B (zh) 2022-09-30
EP3632910A4 (en) 2021-02-24
EP3632910A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
CN110662743B (zh) 作为fxr受体激动剂的内酰胺类化合物
JP6861858B2 (ja) Ｓｓａｏ阻害剤
JP6754505B2 (ja) Ａｓｋ１阻害剤、その調製方法および使用
CN106459009B (zh) 丙肝病毒抑制剂及其制药用途
CA3050346A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
CA3133753A1 (en) Novel small molecule inhibitors of tead transcription factors
JP7323603B2 (ja) 三環式縮合フラン置換ピペリジンジオン系化合物
EP3466946B1 (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
JP7237010B2 (ja) Ｈｄａｃ６選択的阻害剤およびその製造方法と使用
CA3054324C (en) Tri-cycle compound and applications thereof
JP7123956B2 (ja) スピロ化合物およびその使用
AU2017251555B2 (en) Pyridone derivative comprising heteroatomic ring butane substituent, for treating fibrosis and inflammatory diseases
JP6262885B2 (ja) オレキシン受容体拮抗剤としてのピペリジン誘導体
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
CN114845996B (zh) 一种含苯环的化合物及其应用
WO1998046569A1 (fr) Derives de benzene
WO2023114819A1 (en) Tetraline, phenylcyclobutane, and phenylcyclopentane analogs as rxfp1 agonists
KR20170067728A (ko) 아미노설포닐계 화합물, 이의 제조 방법 및 용도
RU2776052C2 (ru) Лактамное соединение в качестве агониста рецептора FXR
AU2022228430A1 (en) Diazepine derivatives useful in the treatment of clostridium difficile
CN106065012A (zh) 咪唑类化合物
CN108017643A (zh) 一种含有氮杂环螺旋结构的高效ido/tdo双抑制剂
KR910010081B1 (ko) 니트로아포빈카민산 유도체의 제조방법
CA3234990A1 (en) Rxfp1 agonists
WO2020148325A1 (en) Neutral lxr modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017900

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20201207

Address after: No.226, Huanghe Avenue, high tech Industrial Development Zone, Shijiazhuang, Hebei Province

Applicant after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Address before: Room 218, business office building, No.9, Gaoxin Road, Jiangbei new district, Nanjing, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant